Frontage has developed sensitive and reliable assays for the detection of germline and somatic variants in cancer-related genes from a variety of sample types.

Our NGS and PCR-based assays allow rapid and direct analysis of pathogenic genetic variants involved in a variety of cancers, providing an essential tool for biomarker discovery, patient stratification, and CDx support.  

Providing insight into cancer through DNA sequence analysis 

Oncology Services Highlights 

Somatic & Germline Variant Detection 

Scientists at Frontage have expertise in somatic and germline variant detection using next-generation sequencing (NGS) and PCR-based approaches (qPCR or ddPCR). Our state-of-the-art technologies and optimized methods allow for highly accurate, specific, and sensitive variant detection from a variety of sample types. Frontage offers a fully validated oncology NGS panel and workflow for detecting germline variants and somatic mutations from blood, tumor samples, and circulating tumor DNA (ctDNA). We also have extensive experience in designing and optimizing qPCR and ddPCR assays for variant detection. Our genomics team can work with you to determine which assay type is best for your specific needs.  

Oncology NGS Panels 

The genomics team at Frontage has designed a targeted, next-generation sequencing (NGS) approach that allows for the rapid and direct analysis of pathogenic variants involved in a variety of cancer types. Our oncology panel has been expertly designed to detect hereditary variants and somatic mutations in hundreds of known cancer-related genes, providing an essential tool for biomarker discovery, patient stratification, and clinical trial support.   

Frontage offers CLIA/CAP-accredited LDTs for the detection of germline variants from blood or buccal swabs, somatic variant detection from tumor tissue (FFPE or frozen), and the detection of somatic variants from cell-free circulating tumor DNA (ctDNA). We also provide bioinformatics services, variant classification, and personalized clinical reports.   

Liquid Biopsy & ctDNA 

The genomics team at Frontage has expert experience with a wide array of liquid biopsy assays, including variant detection from circulating tumor DNA (ctDNA), cell-free DNA (cfDNA) methylation profiling, RNA-seq, and exosome analysis.  

Accurate Variant Detection from ctDNA 

Frontage offers analysis of cfDNA and ctDNA for detection and quantification of somatic mutations in cancer-related genes to allow disease detection and monitoring with minimally invasive strategies. Isolated cfDNA can be examined by NGS using our fully validated oncology panel. Alternatively, ddPCR allows for a more focused approach to identify specific variants in a smaller subset of genes. For more information, click here.  

End-to-End Exosome Analysis 

Frontage provides end-to-end exosome analysis services, including exosome isolation, purification, and characterization. Our scientific team can identify the size distribution and concentration of exosomes present in the biosample prior to subsequent analysis to provide a first characterization of exosomes potentially involved in disease. Frontage also provides a comprehensive solution for exosomal RNA profiling of both small and long RNA. Our genomics team can isolate exosomes from a variety of sample types using a wide range of techniques well-suited for large volume samples.  

Our genomics team has expert experience working with a variety of sample types, including whole blood, serum, plasma, urine, saliva, cerebrospinal fluid, lavage, and more.  

Bioinformatics, Variant Classification & Clinical Reports 

Frontage offers expert data analysis and interpretation. We offer a suite of statistical analyses for our NGS, PCR-based, and other genomic assays. At Frontage, we have developed state-of-the-art bioinformatics pipelines for various NGS applications, including germline and somatic variant detection, small and long RNA-sequencing analysis, tumor clonal analysis and tumor mutational burden. The end-to-end oncology services at Frontage include variant annotation and classification to identify pathogenic variants using the mor comprehensive and current databases and guidelines, as well as customizable report generation for each sample.